HMGB1 and multiple sclerosis: In an in vivo model of multiple sclerosis, animals injected with 0.08 mg kg−1 of tibolone showed less reactive gliosis, in parallel with a significant decrease in the overexpression of TLR4, high mobility group box 1 (HMGB1), NF-kB, and the NLR family pyrin domain–containing 3 (NLRP3) inflammasome, suggesting that tibolone may exert anti-apoptotic effects by reducing inflammation, possibly mediated by ERβ [19,20,21].